Emerging role of complement in ocular diseases

Current Immunology Reviews

Volumn 7, Issue 3, 2011, Pages 360-367

  Bora, Nalini S ^a   Jha, Purushottam ^a   Lyzogubov, Valeriy V ^a   Bora, Puran S ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Age related macular degeneration; Complement regulatory proteins; Complement system; Diabetic retinopathy; Glaucoma; Uveitis

Indexed keywords

CD59 ANTIGEN; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4 BINDING PROTEIN; COMPLEMENT COMPONENT C5A; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; COMPLEMENT MEMBRANE ATTACK COMPLEX; DECAY ACCELERATING FACTOR; GLUCOSE; LECTIN; MEMBRANE COFACTOR PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN; STEROID;

AGING; ANTIGEN ANTIBODY COMPLEX; AQUEOUS HUMOR; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL DEATH; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CHOROID; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DIABETIC RETINOPATHY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; ENZYME INHIBITION; EYE DISEASE; EYE INFLAMMATION; EYE PROTECTION; GENE MUTATION; GLAUCOMA; GLUCOSE BLOOD LEVEL; HEREDITY; HOST RESISTANCE; HUMAN; HYPERTENSION; IMMUNE SYSTEM; IMMUNIZATION; INNATE IMMUNITY; IRIS; NONHUMAN; OBESITY; OPTIC NERVE; PHOTORECEPTOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA GANGLION CELL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SMOKING; STEROID THERAPY; TISSUE INJURY; UNSPECIFIED SIDE EFFECT; UVEITIS; VITREOUS BODY;

EID: 79959925216     PISSN: 15733955     EISSN: 1875631X     Source Type: Journal    
DOI: 10.2174/157339511796196656     Document Type: Review

References (97)

1. Atkinson JP, Frank MM. Complement. In: Parker CW Ed, Clinical Immunology. Philadelphia, WB Saunders. 1980; 219-71.
2. Morgan BP, Marchbank KJ, Longhi MP, Harris CL, Gallimore AM. Complement: central to innate immunity and bridging to adaptive responses. Immunol Lett 2005; 97(2): 171-9.
3. Morgan BP, Harris CL. The complement system. In: Morgan BP and Harris CL Eds, Complement regulatory proteins. San Diego, Academic. 1999; 1-13.
4. Sohn JH, Kaplan HJ, Suk HJ, Bora PS, Bora NS. Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59. Invest Ophthalmol Vis Sci 2000; 41(13): 4195-202.
5. Takizawa H, Okada N, Okada H. Complement inhibitor of rat cell membrane resembling mouse Crry/p65. J Immunol 1994; 152: 3032-8.
6. Mondino BJ, Ratajczak HV, Goldberg DB, Schanzlin DJ, Brown SI. Alternate and classical pathway components of complement in the normal cornea. Arch Ophthalmol 1980; 98(2): 346-9.
7. Mondino BJ, Rao H. Hemolytic complement activity in aqueous humor. Arch Ophthalmol 1983; 101(3): 465-8.
8. Bora NS, Gobleman CL, Atkinson JP, Pepose JS, Kaplan HJ. Differential expression of the complement regulatory proteins in the human eye. Invest Ophthalmol Vis Sci 1993; 34(13): 3579-3584.
9. Sohn JH, Kaplan HJ, Suk HJ, Bora PS, Bora NS. Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins. Invest Ophthalmol Vis Sci 2000; 41(11): 3492-3502.
10. Willcox MD, Morris CA, Thakur A, Sack RA, Wickson J, Boey W. Complement and complement regulatory proteins in human tears. Invest Ophthalmol Vis Sci 1997; 38(1): 1-8.
11. Lass JH, Walter EI, Burris TE, et al. Expression of two molecular forms of the complement decay-accelerating factor in the eye and lacrimal gland. Invest Ophthalmol Vis Sci 1990; 31(6): 1136-48.
12. Sohn JH, Bora PS, Suk HJ, Molina H, Kaplan HJ, Bora NS. Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells. Nat Med 2003; 9(2): 206-12.
13. Jha P, Bora PS, Sohn JH, Kaplan HJ, Bora NS. Complement system and the eye. Adv Exp Med Biol 2006; 586: 53-62.
14. Silverstein AM. Changing trends in the etiologic diagnosis of uveitis. Doc Ophthalmol 1997; 94(1-2): 25-37.
15. Bora NS, Kaplan HJ. Intraocular diseases - anterior uveitis. Chem Immunol Allergy 2007; 92: 213-20.
16. Smith JR, Hart PH, Williams KA. Basic pathogenic mechanisms operating in experimental models of acute anterior uveitis. Immunol Cell Biol 1998; 76(6): 497-512.
17. Wacker WB, Donoso LA, Kalsow CM, Yankeelov JA, Organisciak DT. Experimental allergic uveitis. Isolation, characterization, and localization of a soluble uveitopathogenic antigen from bovine retina. J Immunol 1977; 119: 1949-58.
18. Broekhuyse RM, Kuhlmann ED. Experimental autoimmune anterior uveitis. The preparation of uveitogenic melanin. Invest Ophthalmol Vis Sci 1993; 34: 698-700.
19. [Bora NS, Kim MC, Kabeer NH, et al. Experimental autoimmune anterior uveitis. Induction with melanin-associated antigen from the iris and ciliary body. Invest Ophthalmol Vis Sci 1995; 36(6): 1056-66.
20. Kim MC, Kabeer NH, Tandhasetti MT, Kaplan HJ, Bora NS. Immunohistochemical studies in melanin associated antigen (MAA) induced experimental autoimmune anterior uveitis (EAAU). Curr. Eye Res 1995; 14: 703-710.
21. Bora NS, Woon MD, Tandhasetti MT, Cirrito TP, Kaplan HJ. Induction of experimental autoimmune anterior uveitis by a selfantigen: melanin complex without adjuvant. Invest Ophthalmol Vis Sci 1997; 38: 2171-5.
22. Bora, NS, Sohn JH, Kang SG, et al. Type I collagen is the autoantigen in experimental autoimmune anterior uveitis. J Immunol 2004; 172(11): 7086-94.
23. Jha P, Sohn JH, Xu Q, et al. The complement system plays a critical role in the development of experimental autoimmune anterior uveitis. Invest Ophthalmol Vis Sci 2006; 47: 1030-8.
24. Jha P, Sohn JH, Xu Q, et al. Suppression of complement regulatory proteins (CRPs) exacerbates experimental autoimmune anterior uveitis (EAAU). J Immunol 2006; 176: 7221-31.
25. Jha P, Matta B, Lyzogubov V, Tytarenko R, Bora PS, Bora NS. Crucial role of apoptosis in the resolution of experimental autoimmune anterior uveitis. Invest Ophthalmol Vis Sci 2007; 48: 5091-100.
26. Matta B, Jha P, Bora PS, Bora NS. Tolerance to melanin-associated antigen in autoimmune uveitis is mediated by CD4+CD25+ Tregulatory cells. Am J Pathol 2008; 173: 1440-54.
27. Jha P, Manickam B, Matta B, Bora PS, Bora NS. Proteolytic cleavage of type I collagen generates an autoantigen in autoimmune uveitis. J Biol Chem 2009; 284(45): 31401-31411.
28. Rosenbaum JT, McDevitt HO, Guss RB, Egbert PR. Endotoxininduced uveitis in rats as a model for human disease. Nature 1980; 286: 611-3.
29. Mondino BJ, Glovsky MM, Ghekiere L. Activated complement in inflamed aqueous humor. Invest Ophthalmol Vis Sci 1984; 25: 871-3.
30. Okada M, Shimada K. Effects of various pharmacologic agents on allergic inflammation of the eye. The roles of chemical mediators in ocular inflammation. Invest Ophthalmol Vis Sci 1980; 19(2): 176-81.
31. Marak GE, Wacker WB, Rao NA, Jack R, Ward PA. Effects of complement depletion on experimental allergic uveitis. Ophthalmic Res 1979; 11: 97-107.
32. Read RW, Szalai AJ, Vogt SD, McGwin G, Barnum SR. Genetic deficiency of C3 as well as CNS-targeted expression of the complement inhibitor sCrry ameliorates experimental autoimmune uveoretinitis. Exp Eye Res 2006; 82(3): 389-94.
33. An F, Li Q, Tu Z, et al. Role of DAF in protecting against T-cell autoreactivity that leads to experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 2009; 50(8): 3778-82.
34. Visual impairment and blindness, Word Health Organization, Fact Sheet No 282, May 2009.
35. Coleman HR, Chan CC, Ferris FL 3rd, Chew EY. Age-related macular degeneration. Lancet 2008; 372(9652): 1835-45.
36. Friedman DS, O'Colmain BJ, Muñoz B, et al. Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004; 122(4): 564-72.
37. Jha P, Bora PS, Bora NS. The role of complement system in ocular diseases including uveitis and macular degeneration. Mol Immunol 2007; 44(16): 3901-8.
38. Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Age-related macular degeneration--emerging pathogenetic and therapeutic concepts. Ann Med 2006; 38(7): 450-71.
39. Campochiaro PA. Retinal and choroidal neovascularization. J Cell Physiol 2000; 184(3): 301-10.
40. Bora PS, Sohn JH, Cruz JM, et al. Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J Immunol 2005; 174(1): 491-7.
41. Haddad S, Chen CA, Santangelo SL, Seddon JM. The genetics of age-related macular degeneration: a review of progress to date. Surv Ophthalmol 2006; 51(4): 316-63.
42. Donoso LA, Kim D, Frost A, Callahan A, Hageman G. The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2006; 51(2): 137-52.
43. Miller H, Miller B, Ishibashi T, Ryan SJ. Pathogenesis of laserinduced choroidal subretinal neovascularization. Invest Ophthalmol Vis Sci 1990; 31(5): 899-908.
44. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308: 385-9.
45. Schaumberg DA, Hankinson SE, Guo Q, Rimm E, Hunter DJ. A prospective study of 2 major age-related macular degeneration susceptibility alleles and interactions with modifiable risk factors. Arch Ophthalmol 2007; 125(1): 55-62.
46. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004; 122(4): 598-614.
47. Sohn JH, Bora PS, Jha P, Tezel TH, Kaplan HJ, Bora NS. Complement, innate immunity and ocular disease. Chem Immunol Allergy 2007; 92: 105-14.
48. Bora NS, Jha P, Bora PS. The role of complement in ocular pathology. Semin Immunopathol 2008; 30(2): 85-95.
49. Nozaki M, Raisier BJ, Sakurai E, et al. Drusen complement component C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci USA. 2006; 103: 2328-33.
50. Meri S. Loss of self-control in the complement system and innate autoreactivity. Ann N Y Acad Sci 2007; 1109: 93-105.
51. Bora NS, Kaliappan S, Jha P, et al. CD59, a complement regulatory protein, controls choroidal neovascularization in a mouse model of wet-type age-related macular degeneration. J Immunol 2007; 178(3): 1783-90.
52. Zhou J, Kim SR, Westlund BS, Sparrow JR. Complement activation by bisretinoid constituents of RPE lipofuscin. Invest Ophthalmol Vis Sci 2009; 50(3): 1392-9.
53. Zhou J, Jang YP, Kim SR, Sparrow JR. Complement activation by photooxidation products of A2E, a lipofuscin constituent of the retinal pigment epithelium. Proc Natl Acad Sci U S A 2006; 103(44): 16182-7.
54. Chen M, Forrester JV, Xu H. Synthesis of complement factor H by retinal pigment epithelial cells is down-regulated by oxidized photoreceptor outer segments. Exp Eye Res 2007; 84(4): 635-45.
55. Javitt NB, Javitt JC. The retinal oxysterol pathway: a unifying hypothesis for the cause of age-related macular degeneration. Curr Opin Ophthalmol 2009; 20(3): 151-7.
56. [Thurman JM, Renner B, Kunchithapautham K, et al. Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury. J Biol Chem 2009; 284(25):16939-47.
57. Wu Z, Lauer TW, Sick A, Hackett SF, Campochiaro PA. Oxidative stress modulates complement factor H expression in retinal pigmented epithelial cells by acetylation of FOXP3. J Biol Chem 2007; 282(31): 22414-25.
58. Seddon JM, Reynolds R, Maller J, Fagerness JA, Daly MJ, Rosner B. Prediction model for prevalence and incidence of advanced agerelated macular degeneration based on genetic, demographic, and environmental variables. Invest Ophthalmol Vis Sci 2009; 50(5): 2044-53.
59. Doney AS, Leese GP, Olson J, Morris AD, Palmer CN. The Y402H variant of complement factor H is associated with agerelated macular degeneration but not with diabetic retinal disease in the Go-DARTS study. Diabet Med 2009; 26(5): 460-5.
60. Lommatzsch A, Hermans P, Weber B, Pauleikhoff D. Complement factor H variant Y402H and basal laminar deposits in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007; 245(11): 1713-6.
61. Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with agerelated macular degeneration. Nat Genet 2006; 38(4): 458-62.
62. Maller J, George S, Purcell S, et al. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat Genet 2006; 38(9):1055-9.
63. Maller JB, Fagerness JA, Reynolds RC, Neale BM, Daly MJ, Seddon JM. Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat Genet 2007; 39(10): 1200-1.
64. Fagerness JA, Maller JB, Neale BM, Reynolds RC, Daly MJ, Seddon JM. Variation near complement factor I is associated with risk of advanced AMD. Eur J Hum Genet 2009; 17(1): 100-4.
65. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A 2005; 102(20): 7227-32.
66. Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sanchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 2004; 41(4): 355-67.
67. Zipfel PF, Hallström T, Hammerschmidt S, Skerka C. The complement fitness factor H: role in human diseases and for immune escape of pathogens, like pneumococci. Vaccine 2008; 26 (Suppl 8): I67-74.
68. Edwards AO, Ritter R, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science 2005; 308: 421-4.
69. Gu J, Paeur GJ, Yue X, et al. Clinical Genomic And Proteomic Study Group. Assessing susceptibility to age-related macular degeneration with proteomic and genomic biomarkers. Mol Cell Proteomics 2009; 8(6): 1338-49.
70. Skerka C, Lauer N, Weinberger AA, et al. Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. Mol Immunol 2007; 44(13):3398-406.
71. Bora NS, Kaliappan S, Jha P, et al. Complement activation via alternative pathway is critical in the development of laser-induced choroidal neovascularization: role of factor B and factor H. J Immunol 2006; 177(3):1872-8.
72. Esparza-Gordillo J, Soria JM, Buil A, et al. Genetic and environmental factors influencing the human factor H plasma levels. Immunogenetics 2004; 56(2): 77-82.
73. Kew RR, Ghebrehiwet B, Janoff A. Cigarette smoke can activate the alternative pathway of complement in vitro by modifying the third component of complement. J Clin Invest 1985; 75(3): 1000-7.
74. Bykov I, Junnikkala S, Pekna M, Lindros KO, Meri S. Effect of chronic ethanol consumption on the expression of complement components and acute-phase proteins in liver. Clin Immunol 2007; 124(2): 213-20.
75. Kaliappan S, Jha P, Lyzogubov VV, Tytarenko RG, Bora NS, Bora PS. Alcohol and nicotine consumption exacerbates choroidal neovascularization by modulating the regulation of complement system. FEBS Lett 2008; 582(23-24): 3451-8.
76. Bora PS, Kaliappan S, Xu Q, et al. Alcohol linked to enhanced angiogenesis in rat model of choroidal neovascularization. FEBS J 2006; 273(7): 1403-14.
77. Rivera JL, Bell NP, Feldman RM. Risk factors for primary open angle glaucoma progression: what we know and what we need to know. Curr Opin Ophthalmol 2008; 19(2): 102-106.
78. Nickells RW. From ocular hypertension to ganglion cell death: a theoretical sequence of events leading to glaucoma. Can J Ophthalmol 2007; 42(2): 278-87.
79. Grus F, Sun D. Immunological mechanisms in glaucoma. Semin Immunopathol 2008; 30(2): 121-126.
80. Grus FH, Joachim SC, Wuenschig D, Rieck J, Pfeiffer N. Autoimmunity and glaucoma. J Glaucoma 2008; 17(1): 79-84.
81. Miyahara T, Kikuchi T, Akimoto M, Kurokawa T, Shibuki H, Yoshimura N. Gene microarray analysis of experimental glaucomatous retina from cynomologous monkey. Invest Ophthalmol Vis Sci 2003; 44(10): 4347-56.
82. Ahmed F, Brown KM, Stephan DA, Morrison JC, Johnson EC, Tomarev SI. Microarray analysis of changes in mRNA levels in the rat retina after experimental elevation of intraocular pressure. Invest Ophthalmol Vis Sci 2004; 45(4): 1247-58.
83. [Stasi K, Nagel D, Yang X, et al. Complement component 1Q (C1Q) upregulation in retina of murine, primate, and human glaucomatous eyes. Invest Ophthalmol Vis Sci 2006; 47(3): 1024-9.
84. Kuehn MH, Kim CY, Ostojic J, et al. Retinal synthesis and deposition of complement components induced by ocular hypertension. Exp Eye Res 2006; 83(3): 620-8.
85. Kuehn MH, Kim CY, Jiang B, Dumitrescu AV, Kwon YH. Disruption of the complement cascade delays retinal ganglion cell death following retinal ischemia-reperfusion. Exp Eye Res 2008; 87(2): 89-95.
86. Hughes J, Nangaku M, Alpers CE, Shankland SJ, Couser WG, Johnson RJ. C5b-9 membrane attack complex mediates endothelial cell apoptosis in experimental glomerulonephritis. Am J Physiol Renal Physiol 2000; 278: F747-F757.
87. Singhrao SK, Neal JW, Rushmere NK, Morgan BP, Gasque P. Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis. Am J Pathol 2000; 157(3): 905-18.
88. Topouzis F, Anastasopoulos E, Augood C, et al. Association of diabetes with age-related macular degeneration in the EUREYE study. Br J Ophthalmol 2009; 93(8): 1037-41.
89. Gerl VB, Bohl J, Pitz S, Stoffelns B, Pfeiffer N, Bhakdi S. Extensive deposits of complement C3d and C5b-9 in the choriocapillaris of eyes of patients with diabetic retinopathy. Invest Ophthalmol Vis Sci 2002; 43(4): 1104-8.
90. Zhang J, Gerhardinger C, Lorenzi M. Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes 2002; 51(12): 3499-504.
91. Grisanti S, Wiedemann P, Weller M, Heimann K, Zilles K. The significance of complement in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1991; 32(10): 2711-7.
92. Giusti C. Are phospholipid-binding antibodies implicated in the pathogenesis of diabetic microangiopathy? Med Hypotheses 2004; 63(2): 235-8.
93. Dagher Z, Park YS, Asnaghi V, Hoehn T, Gerhardinger C, Lorenzi M. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes 2004; 53(9): 2404-11.
94. Sun W, Oates PJ, Coutcher JB, Gerhardinger C, Lorenzi M. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes 2006; 55(10): 2757-62.
95. Hidayat AA, Fine BS. Diabetic choroidopathy. Light and electron microscopic observations of seven cases. Ophthalmology 1985; 92(4): 512-22.
96. Fryczkowski AW, Hodes BL, Walker J. Diabetic choroidal and iris vasculature scanning electron microscopy findings. Int Ophthalmol 1989; 13(4): 269-79.
97. Cao J, McLeod S, Merges CA, Lutty GA. Choriocapillaris degeneration and related pathologic changes in human diabetic eyes. Arch Ophthalmol 1998; 116(5): 589-97.